Table 2.

Demographic and Clinical Characteristics.

	Entire Cohort (N=363)	Reduced Cohort (N=223)
Age (Year)	45.9 (12.7) 47.0 [37.0, 55.0]	47.2 (12.0) 48.0 [38.0, 55.0]
Sex = Female	134 (0.37)	76 (0.34)
Race
Caucasian American	266 (0.73)	164 (0.74)
African American	83 (0.23)	50 (0.22)
Hispanic	4 (0.01)	3 (0.01)
Asian	5 (0.01)	3 (0.01)
Other	3 (0.01)	3 (0.01)
Undisclosed	2 (0.01)	0 (0.00)
Weight (kg)	82.9 (20.8) 81.2 [66.7, 95.3]	83.0 (20.7) 80.0 [66.4, 94.9]
Hemoglobin (g/dL)	12.5 (2.1) 12.5 [11.1, 14.0]	12.6 (2.0) 12.5 [11.1, 14.0]
Albumin (g/dL)	4.1 (0.4) 4.1 [3.9, 4.4]	4.1 (0.4) 4.1 [3.8, 4.4]
Proportion of concentrations with extracted last-dose time	0.52	0.73
Twice-daily tacrolimus dose (mg)	3.4 (1.8) 3 [2, 4]	3.1 (1.7) 3 [2, 4]
Tacrolimus blood concentration (ng/mL)	7.6 (3.1) 7.1 [5.5, 9.0]	7.5 (3.0) 7.1 [5.5, 8.9]
Number of concentration levels per subject	9.0 (1.8) 9.0 [10.0, 10.0]	9.5 (1.2) 10.0 [10.0, 10.0]
Total number of concentrations	3258	2116
Total days of follow-up	588 (295) 557 [361, 854]	525 (268) 482 [324, 686]

Population characteristics of the entire cohort (left) and the reduced cohort (right). Values are presented as count (proportion) for categorical variables and mean (SD) median [interquartile range] for continuous variables.